SynthesisFrontiers in immunology2026
Meta-analysis and systematic review: the association between rheumatoid arthritis and the risk of thyroid cancer.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid Arthritis (RA), as a common autoimmune disease, not only causes damage to the joints themselves, but also increases the risk of developing other diseases. In recent years, the association between RA and malignant tumors has attracted increasing attention. Most studies have found that RA is associated with site-specific alterations in malignancy risk rather than a uniformly increased risk of all cancers. However, the risk of thyroid cancer in RA patients remains controversial. Different studies even yield contradictory results. Notably, to date, no systematic review or meta-analysis has specifically evaluated this association. Therefore, this meta-analysis aimed to estimate the association between RA and the risk of thyroid cancer, providing evidence for clinical cancer surveillance strategies. Methods: The search was conducted from database inception to October 2025 in PubMed, EMBASE, and Web of Science databases. Studies that estimated the association between rheumatoid arthritis (RA) and the incidence of thyroid cancer using hazard ratio (HR) or standardized incidence ratio (SIR) and 95% confidence interval (CI) were included. Two researchers independently screened the literature, extracted the data, and evaluated the risk of bias of the included studies. Meta-analysis was performed using RevMan 5.3 software. This meta-analysis was registered on the PROSPERO platform (CRD420251267552). Results: A total of fourteen cohort studies were included, involving 1,970,165 participants. The meta-analysis indicated that patients with RA have a higher risk of developing thyroid cancer compared to the general population (HR = 1.28, 95%CI: 1.05-1.55, P = 0.01). The subgroup analysis showed that RA in the Chinese population increased the risk of thyroid cancer (HR = 1.79, 95% CI: 1.26-2.54, P = 0.001). There was no association between RA in other populations and the risk of thyroid cancer (HR = 1.01, 95% CI: 0.85-1.21, P = 0.88). RA did not increase the risk of thyroid cancer under parsimonious adjustment (adjusted only for age and/or sex) (HR = 1.03, 95% CI: 0.73-1.44, Conclusions: The existing evidence suggests that RA may be associated with the risk of thyroid cancer. Given the limitations of this study, well-designed prospective studies with appropriate confounding controls are needed to further verify this association. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251267552.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.